Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - beclometasondipropionat, formoterolfumarat dihydrat - inhalationsspray, opløsning - 100+6 mikrog./dosis

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

orion corporation - beclometasondipropionat, formoterolfumarat dihydrat - inhalationsspray, opløsning - 100+6 mikrog./dosis

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

orion corporation - beclometasondipropionat, formoterolfumarat dihydrat - inhalationsspray, opløsning - 200+6 mikrog./dosis

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

viatris limited - beclometasondipropionat, formoterolfumarat dihydrat - inhalationsspray, opløsning - 100+6 mikrog/dosis

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

bruschettini - mometasonfuroat monohydrat - næsespray, suspension - 50 mikrogram/dosis

Den Europæiske Union - dansk - EMA (European Medicines Agency)

sanofi winthrop industrie - dronedaron - atrieflimren - hjertetapi - multaq er indiceret til vedligeholdelse af sinusrytme efter vellykket kardioversion i voksen klinisk stabile patienter med paroxysmal og vedvarende atrieflimren (af). på grund af dets sikkerhedsprofil bør multaq kun ordineres efter, at alternative behandlingsmuligheder er blevet overvejet. multaq bør ikke gives til patienter med venstre ventrikel systolisk dysfunktion eller til patienter med nuværende eller tidligere episoder af hjertesvigt.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

astrazeneca ab - reassortant influenzavirus (levende svækket) af følgende stamme: a / vietnam / 1203/2004 (h5n1) stamme - influenza, human - vacciner - profylakse af influenza i en officielt erklæret pandemisk situation hos børn og unge fra 12 måneder til under 18 år. pandemic influenza vaccine h5n1 astrazeneca bør anvendes i overensstemmelse med officielle retningslinjer.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

takeda pharma a/s - fentanyl citrate - pain; cancer - analgetika - instanyl er indiceret til behandling af gennembrudssmerter hos voksne, der allerede modtager opioidbehandling ved vedligeholdelse af kronisk kræftpine. gennembrudssmerter er en forbigående forværring af smerte, der opstår på baggrund af ellers kontrolleret vedvarende smerte.  patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

pfizer europe ma eeig - tofacitinib - arthritis, reumatoid - immunosuppressiva - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 og 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

gilead sciences ireland uc, galapagos nv - filgotinib maleate - arthritis, reumatoid - immunosuppressiva - rheumatoid arthritisjyseleca is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). jyseleca may be used as monotherapy or in combination with methotrexate (mtx). ulcerative colitisjyseleca is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.